FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2342723686> ?p ?o ?g. }

• W2342723686 abstract "Abstract Background Progress in the treatment of acute myeloid leukemia (AML) in older patients (pts) is still limited with poor complete remission (CR) rate and overall survival (OS). This is attributed to a variety of reasons including an inherently poor biology, especially a higher incidence of poor-risk karyotypes, co-morbidities, and an age-related functional impairment. In our randomized AML HD98B trial, the addition of all-trans retinoic acid (ATRA) to intensive chemotherapy resulted in an increased CR rate, event-free (EFS) and OS (Schlenk et al Leukemia 2004). More recent reports on in vitro studies indicated a synergistic action of the histone deacetylase inhibitor valproic acid (VPA) when associated with ATRA plus cytarabine and anthracyclines. In the randomized AMLSG 06-04 trial, therefore, VPA was evaluated in combination with intensive induction therapy plus ATRA in older pts (>60 years) with newly diagnosed AML. In first analyses, the addition of VPA did not provide a significant advantage in OS and EFS after a median follow-up of 47 months (Tassara et al, ASH 2010, abstract #185). This was mainly due to increased hematological toxicity by VPA after the second induction therapy. Here we provide updated analyses especially on survival outcome data based on mature follow-up. Aims To evaluate VPA in combination with intensive induction therapy and ATRA in older patients with newly diagnosed AML. Methods Between August 2004 and February 2006 186 patients were randomized (standard-arm, n=93; experimental-arm, n=93) in the AMLSG 06-04 study (ClinicalTrials.gov Identifier: NCT00151255); median age was 68 years (60-84). The first 77 pts were randomized to receive 2 induction cycles (idarubicin 12 mg/m2 i.v. days 1-3, cytarabine 100 mg/m2 cont. i.v. days 1-5, ATRA 45 mg/m2 days 3-5 and 15 mg/m2 days 6-28) with or without VPA (days 1-28; started at 400 mg bid and then adapted in order to obtain a serum level of 60-150 mg/l). After an interim analysis the study was amended; for the following 109 patients idarubicin was dose-reduced to day 1 and 3 and VPA only added during the first induction cycle. All patients were intended for consolidation. Molecular diagnostics were performed as previously published (Schlenk et al, Haematologica 2009) Results Details of the response rate and toxicity of the induction treatment have already been presented (Tassara et al, ASH 2010, abstract #185). To summarize, CR rates after double induction were in trend higher in the standard-arm (52% vs. 40%; p=0.10), and early death rate higher in the experimental-arm (14% vs. 26%; p=0.06). The main toxicities attributed to VPA were grade 3/4 infections and delayed hematologic recovery (leukocytes, neutrophils and platelets) observed after the second induction cycle. Therapy (i.e. double induction and consolidation) was completed by 37/93 (40%) of patients in the standard arm and 19/93 (20%) in the experimental arm (p=0.01) After a median follow up of 84 months, analysis of the primary endpoint EFS revealed no differences between the two arms (EFS at 5 years, standard arm 2.3%, experimental arm 7.6%; p=0.95); similarly OS was not different (OS at 5 years, standard arm 11.7%, experimental arm 11.4%; p=0.57). However, pts in the experimental arm had a significantly better relapse-free survival (RFS at 5 years, standard arm 6.4%, experimental arm 24.0%, p=0.02). In explorative subset analyses superior RFS (p=0.03) and OS (p=0.03) of CR-patients were observed in AML patients with mutated NPM1 randomized into the experimental arm (RFS at 5 years, standard arm 8%, experimental arm 42%; OS at 5 years, standard arm 37%, experimental arm 52%). In contrast no differences were seen in AML patients with NPM1 wild-type for RFS (p=0.13) and OS (p=0.87) of CR-patients (RFS at 5 years, standard arm 7%, experimental arm 20%; OS at 5 years, standard arm 15%, experimental arm 22%). Due to a low frequency of FLT3-ITD (9/72) in this patient subset meaningful analyses were not possible. Conclusion In older patients with AML, the addition of VPA to standard induction treatment was associated with severe hematological toxicity as well as higher rates of infections and did not improve EFS and OS. However, after a long follow-up VPA was associated with a significantly improved RFS, which might be related to the mutated NPM1 genotype. Disclosures: Schlenk: Celgene: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Chugai: Research Funding; Amgen: Research Funding; Novartis: Research Funding; Ambit: Honoraria." @default.
• W2342723686 created "2016-06-24" @default.
• W2342723686 creator A5003253888 @default.
• W2342723686 creator A5013435653 @default.
• W2342723686 creator A5014277422 @default.
• W2342723686 creator A5017638217 @default.
• W2342723686 creator A5022178280 @default.
• W2342723686 creator A5026967725 @default.
• W2342723686 creator A5029448872 @default.
• W2342723686 creator A5030925393 @default.
• W2342723686 creator A5036204725 @default.
• W2342723686 creator A5039994927 @default.
• W2342723686 creator A5041544709 @default.
• W2342723686 creator A5042780466 @default.
• W2342723686 creator A5046761240 @default.
• W2342723686 creator A5052721036 @default.
• W2342723686 creator A5053949970 @default.
• W2342723686 creator A5053983155 @default.
• W2342723686 creator A5055477573 @default.
• W2342723686 creator A5058209680 @default.
• W2342723686 creator A5062688084 @default.
• W2342723686 creator A5070851905 @default.
• W2342723686 creator A5078352756 @default.
• W2342723686 creator A5081614049 @default.
• W2342723686 creator A5081804029 @default.
• W2342723686 creator A5083170898 @default.
• W2342723686 creator A5084493873 @default.
• W2342723686 creator A5089395073 @default.
• W2342723686 date "2013-11-15" @default.
• W2342723686 modified "2023-09-30" @default.
• W2342723686 title "Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSG 06-04 Study" @default.
• W2342723686 doi "https://doi.org/10.1182/blood.v122.21.3927.3927" @default.
• W2342723686 hasPublicationYear "2013" @default.
• W2342723686 type Work @default.
• W2342723686 sameAs 2342723686 @default.
• W2342723686 citedByCount "0" @default.
• W2342723686 crossrefType "journal-article" @default.
• W2342723686 hasAuthorship W2342723686A5003253888 @default.
• W2342723686 hasAuthorship W2342723686A5013435653 @default.
• W2342723686 hasAuthorship W2342723686A5014277422 @default.
• W2342723686 hasAuthorship W2342723686A5017638217 @default.
• W2342723686 hasAuthorship W2342723686A5022178280 @default.
• W2342723686 hasAuthorship W2342723686A5026967725 @default.
• W2342723686 hasAuthorship W2342723686A5029448872 @default.
• W2342723686 hasAuthorship W2342723686A5030925393 @default.
• W2342723686 hasAuthorship W2342723686A5036204725 @default.
• W2342723686 hasAuthorship W2342723686A5039994927 @default.
• W2342723686 hasAuthorship W2342723686A5041544709 @default.
• W2342723686 hasAuthorship W2342723686A5042780466 @default.
• W2342723686 hasAuthorship W2342723686A5046761240 @default.
• W2342723686 hasAuthorship W2342723686A5052721036 @default.
• W2342723686 hasAuthorship W2342723686A5053949970 @default.
• W2342723686 hasAuthorship W2342723686A5053983155 @default.
• W2342723686 hasAuthorship W2342723686A5055477573 @default.
• W2342723686 hasAuthorship W2342723686A5058209680 @default.
• W2342723686 hasAuthorship W2342723686A5062688084 @default.
• W2342723686 hasAuthorship W2342723686A5070851905 @default.
• W2342723686 hasAuthorship W2342723686A5078352756 @default.
• W2342723686 hasAuthorship W2342723686A5081614049 @default.
• W2342723686 hasAuthorship W2342723686A5081804029 @default.
• W2342723686 hasAuthorship W2342723686A5083170898 @default.
• W2342723686 hasAuthorship W2342723686A5084493873 @default.
• W2342723686 hasAuthorship W2342723686A5089395073 @default.
• W2342723686 hasConcept C104317684 @default.
• W2342723686 hasConcept C118552586 @default.
• W2342723686 hasConcept C126322002 @default.
• W2342723686 hasConcept C143998085 @default.
• W2342723686 hasConcept C168563851 @default.
• W2342723686 hasConcept C2777172819 @default.
• W2342723686 hasConcept C2778041864 @default.
• W2342723686 hasConcept C2778186239 @default.
• W2342723686 hasConcept C2778729363 @default.
• W2342723686 hasConcept C2779117419 @default.
• W2342723686 hasConcept C2779963572 @default.
• W2342723686 hasConcept C2781121885 @default.
• W2342723686 hasConcept C55493867 @default.
• W2342723686 hasConcept C71924100 @default.
• W2342723686 hasConcept C86803240 @default.
• W2342723686 hasConcept C90924648 @default.
• W2342723686 hasConcept C98274493 @default.
• W2342723686 hasConceptScore W2342723686C104317684 @default.
• W2342723686 hasConceptScore W2342723686C118552586 @default.
• W2342723686 hasConceptScore W2342723686C126322002 @default.
• W2342723686 hasConceptScore W2342723686C143998085 @default.
• W2342723686 hasConceptScore W2342723686C168563851 @default.
• W2342723686 hasConceptScore W2342723686C2777172819 @default.
• W2342723686 hasConceptScore W2342723686C2778041864 @default.
• W2342723686 hasConceptScore W2342723686C2778186239 @default.
• W2342723686 hasConceptScore W2342723686C2778729363 @default.
• W2342723686 hasConceptScore W2342723686C2779117419 @default.
• W2342723686 hasConceptScore W2342723686C2779963572 @default.
• W2342723686 hasConceptScore W2342723686C2781121885 @default.
• W2342723686 hasConceptScore W2342723686C55493867 @default.
• W2342723686 hasConceptScore W2342723686C71924100 @default.
• W2342723686 hasConceptScore W2342723686C86803240 @default.
• W2342723686 hasConceptScore W2342723686C90924648 @default.
• W2342723686 hasConceptScore W2342723686C98274493 @default.
• W2342723686 hasLocation W23427236861 @default.
• W2342723686 hasOpenAccess W2342723686 @default.
• W2342723686 hasPrimaryLocation W23427236861 @default.

• next